Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: PFS incontinence therapy

This article was originally published in The Gray Sheet

Executive Summary

PFS incontinence therapy: Health Care Financing Administration affirms its policy of not reimbursing pelvic floor stimulation incontinence therapy, according to Empi, which had sought a national coverage decision. Empi, the manufacturer of the Innova PFS device, notes that PFS is reimbursed only on an "individual appeal basis." Empi maintained that PFS' clinical efficacy is supported by an updated version of the HHS Agency for Health Care Policy & Research urinary incontinence clinical practice guideline, which recommended use of behavioral interventions such as PFS as first-line treatment of urinary incontinence in most cases ("The Gray Sheet" March 18, I&W-12). Empi plans to continue to pursue a change in policy as more data become available on clinical efficacy and cost effectiveness of the technology...

You may also be interested in...



Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

UsernamePublicRestriction

Register

MT005974

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel